Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Mankind Pharma inks pact with Takeda to commercialise Vonoprazan in India
This agreement permits Mankind Pharma to introduce the novel drug, used for treating Gastroesophageal Reflux Disease (GERD), under its own trademark.
- By Newsdesk
- New Delhi
- Jul 16, 2024
Mankind Pharma Limited has announced the signing of a Non-Exclusive Patent License Agreement with Takeda Pharmaceutical to commercialize 'Vonoprazan' in the Indian market. This agreement permits Mankind Pharma to introduce the novel drug, used for treating Gastroesophageal Reflux Disease (GERD), under its own trademark.
Vonoprazan is a potassium-competitive acid blocker (PCAB) designed to treat acid-related disorders, including GERD. It is also effective for conditions such as erosive esophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-esophageal reflux, and reflux esophagitis, and is used in the eradication of Helicobacter pylori, according to Mankind Pharma.
M Ramesh, Executive Vice President of Global Business Development at Mankind Pharma, stated, “By introducing Vonoprazan, we aim to address a significant medical need and enhance the quality of life for those suffering from acid-related illnesses. This new and advanced option for managing acid-related disorders has the potential to offer improved health outcomes and quality of life.”